Interleukin 10 (IL-10) Market: Competitive Landscape, Pipeline, and Market Analysis 2023

Purchase Option

$ 4400
$ 6600
$ 8900

Interleukin 10 (IL-10) is an anti-inflammatory cytokine that plays a vital role in maintaining the balance of immune responses, allowing the clearance of infection while minimizing damage to the host.  It is synthesized by various types of cells in the body, like NK cells, B-cells, and T-cells. It is a pro-inflammatory cytokine that plays a significant role in inhibiting cytokine production and Th1 and Th2 cell activation. Any infection or inflammatory condition that signals an infection in the body against which the level of IL-10 scaled causes an increase in IL-10 levels. Therefore, IL-10  is associated with many diseases like vascular diseases, Rheumatoid Arthritis, Acute Myelogenous Leukemia, Blood Platelet disorders, various kinds of lymphomas like Follicular lymphoma, and others. It has also been linked with many neurodegenerative diseases wherein it played a role in preventing inflammation-mediated neuronal degradation. Hence, it acts to avoid inflammation in disorders such as Multiple Sclerosis, Alzheimer’s disease, Parkinson’s disease, Traumatic Brain Injury, Amyotrophic Lateral Sclerosis (AML), and others. Research is being conducted globally to discover new and novel molecules to be used as H1 Histamine antagonists. The development and launch of new products will thus increase the revenue of the market in the forecasted years. According to the Parkinson’s Foundation, more than 10 million people are living with Parkinson’s disease globally, while 90,000 people are diagnosed with it each year in the USA alone. It is projected that 1.2 million people in the USA will live with Parkinson’s by 2030. Therefore, there is ample opportunity for the market players globally.

A number of these inhibitors are in the market, while many are in ongoing clinical trials. Various companies have various products in their pipelines, with 49 products in different stages of clinical trials, with 2 in Phase 3, 16 in Phase 2, and 7 in Phase 1 of the clinical trials.

Drugs in the Pipeline of IL-10

  • Eyevinal (Ibudilast)
  • Orismilast Oral (LEO 32731)
  • Pegilodecakin (LY3500518)
  • Dekavil (F8-IL10)
  • XT-150
  • AMT-101
  • Galepa (Daleuton Topical)
  • Thykamine (PUR 0110)
  • HMPL-011
  • Tenovil (Ilodecakin)
  • Beta Alethine (Ax-101)
  • ATX-MS-1467
  • BT-063
  • DTRM-555
  • KLS-2031
  • Prevascar (Ilodecakin)
  • AG011
  • AG019
  • APVO210
  • DK210
  • IAE0972
  • XT-150 Intrathecal
  • Faecalibacterium Prausnitzii EXL01-Strain (EXL01)
  • Lenalidomide Subcutaneous Prolonged-Release (NEX-20A)
  • Orismilast Topical (LEO 32731 Topical)

Clinical Activity and Developments of Interleukin 10 (IL-10)

As of June 2023, various companies have approximately 49 products for 581 diseases. For these diseases, many trials are being conducted by players globally. For instance,

  • Cambridge University Hospitals NHS Foundation Trust is conducting a Phase 3 clinical trial to study the efficacy of ibudilast as an adjuvant treatment to Decompressive surgery for Degenerative Cervical myopathy that is expected to complete by September 2026.
  • Union Therapeutics is conducting a Phase 2 clinical trial study on the efficacy and safety of Orismilast in adults with Atopic Dermatitis (AD) that is expected to complete by July 2023.

Molecule name

Number of studies

Eyevinal (ibudilast)


orismilast oral (LEO 32731)


pegilodecakin (LY3500518)


Dekavil (F8-IL10)




Target Indication Analysis of Interleukin 10 (IL-10)

These drugs are in clinical trials for various indications and are being evaluated for safety and efficacy. No drugs in the IL-10 category have been approved by the USFDA for any indication. Drugs are being used that target IL-10 cytokine to treat many diseases and prevent inflammatory responses associated with those diseases causing them. These are used for the treatment of diseases like Rheumatoid Arthritis, Type 2 Diabetes Mellitus, Parkinson’s syndrome, Vascular diseases, Acute Myelogenous Leukemia, Acute Non-Lymphoblastic Leukemia, Follicular lymphoma, Blood disorders and many others. There is an opportunity in the market for the players to launch new products as IL-10 is associated with the pathogenesis of many diseases and hence is a good target.

Frequently Asked Questions

Until now, no IL-10 product has been approved by any regulatory agency around the globe.

These are used for the treatment of diseases like Rheumatoid Arthritis, Type 2 Diabetes Mellitus, Parkinson’s syndrome, Vascular diseases, Acute Myelogenous Leukemia, Acute Non-Lymphoblastic Leukemia, Follicular lymphoma, Blood disorders, and many others.

MediciNova, UNION Therapeutics, Eli Lilly, and Pfizer are some of the major market players for IL-10.

Rising incidence of diseases, improvement in technologies, development of new treatment lines in the market, and changing lifestyles leading to various kinds of neurodegenerative and inflammatory disorders are the key opportunities for IL-10 in the market.

Key Features of the Reports

  • The report provides granular level information about the market size, regional market share, historic market (2019-2023), and forecast (2024-2030)
  • The report covers in-detail insights about the competitor’s overview, company share analysis, key market developments, and their key strategies
  • The report outlines drivers, restraints, unmet needs, and trends that are currently affecting the market
  • The report tracks recent innovations, key developments, and start-up details that are actively working in the market
  • The report provides a plethora of information about market entry strategies, regulatory framework, and reimbursement scenario
  • MediciNova
  • UNION Therapeutics
  • Eli Lilly
  • Pfizer
  • Philogen
  • Xalud Therapeutics
  • Applied Molecular Transport
  • DS Biopharma
  • PurGenesis
  • Hutchmed
  • AxImmune
  • Worg Pharmaceuticals
  • ADMA Biologics
  • Zhejiang DTRM Biopharma
  • Kolon Life Sciences
  • Precigen
  • Medexus
  • Deka BioSciences
  • SunHo BioPharma
  • Exeliom Biosciences
  • Nanexa AB

Adjacent Markets